[Current status of clinical results of new antitumor drugs].
This review describes the current clinical results of phase I and II trials of new antitumor drugs such as the new anthracyclines: epirubicin, idarubicin, esorubicin, carminomycin and marcellomycin; the second generation cisplatin: carboplantin, CHIP, TNO-6, DACCP and JM-40; mitoxantrone, AMSA, AZQ, Tiazofurin, DFMO and others.
D000609:Aminoacridines / Q000627:therapeutic use; D000677:Amsacrine; D018943:Anthracyclines; D000880:Anthraquinones / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use; D016227:Benzoquinones; D016190:Carboplatin; D002360:Carubicin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000518:Eflornithine; D015251:Epirubicin; D006801:Humans; D015255:Idarubicin; D008942:Mitoxantrone; D009279:Naphthacenes / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D009952:Ornithine / Q000031:analogs & derivatives / Q000627:therapeutic use; D012254:Ribavirin / Q000031:analogs & derivatives / Q000627:therapeutic use
D000609:Aminoacridines; D018943:Anthracyclines; D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D001388:Aziridines; D016227:Benzoquinones; D009279:Naphthacenes; D009944:Organoplatinum Compounds; D000677:Amsacrine; C015338:marcellomycin; D015251:Epirubicin; D012254:Ribavirin; C023359:iproplatin; C021967:carboxyphthalato-1,2-diaminocyclohexaneplatinum; D004317:Doxorubicin; D016190:Carboplatin; D008942:Mitoxantrone; D009952:Ornithine; D002360:Carubicin; C029108:diaziquone; C040757:spiroplatin; D002945:Cisplatin; C030851:esorubicin; C033706:tiazofurin; D000518:Eflornithine; D015255:Idarubicin; D003630:Daunorubicin